News
2025-04 – Q1 2025 Reporting
- Draft report SER150 CL-009 was received and will be discussed with the Australian contract organisation and the Serodus biostatistician consultant.
- In March 2025 the company launched a Private Placement with a following Subsequent Offering. The commitment amounted to NOK 20,1 million.
2025-03 – 2024 Annual Report
Serodus AS – Publishes 2024 Annual Report
2024-10 – Q3 2024 Reporting
- Unblinding of the database after SER150 CL-009 was delayed.
- Calculation of SER150 effect on kidney function compared to placebo is consequently also delayed.
2024-08 – Q2 2024 Reporting
- Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated.
- Database for SER150 CL-009 is expected to be unblinded late August or early September.
2024-05 – 2023 Annual Report
Serodus ASA – Publishes 2023 Annual Report